Trillium Asset Management had a proposal that would have required an independent committee to evaluate exploring extraordinary transactions and reporting on the results to shareholders.
"Nucryst is continuing to analyze data from this study so that we can evaluate options for our atopic dermatitis program with a complete understanding of the study results, " says President and CEO Scott H.